ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
37 announcements with these filters
Sai Life Sciences reported FY26 revenue of ₹2,192 Crore, representing 29% growth. Net profit doubled to ₹355 Crore, driven by deep engagement with large pharma customers.
Sai Life Science Ltd reported revenue from operations of ₹602.1 Cr (+3.9% YoY) and net profit of ₹104.2 Cr (+18.0% YoY) for Q4 FY26.
Sai Life Sciences approved its FY2026 audited financial results. Consolidated annual revenue reached ₹21,924.92 million, reflecting significant year-on-year growth and strong operational performance.
Sai Life Sciences announced its Bidar campus transitioned to 100% renewable energy usage. This milestone marks the first Indian CRDMO site to achieve full renewable power.
Sai Life Sciences received a ₹32.86 Crore GST demand order (including interest and penalties) for FY 2021-22 from the Karnataka tax authorities. The demand relates to alleged excess Input Tax Credit availment. The company plans to appeal the order at the Tribunal level and does not expect any material financial impact.
Sai Life Sciences Limited allotted 2,44,281 equity shares upon the exercise of options under its ESOP 2008 and MESOP 2018 plans. The company realized ₹3.38 Crore from this exercise. Following this allotment, the total issued share capital increased to 21,20,23,515 equity shares.
Sai Life Sciences Limited has scheduled a board meeting on May 14, 2026, to approve audited standalone and consolidated financial results for the fiscal year ended March 31, 2026. The company also confirmed that its trading window for designated persons has been closed from April 1, 2026, until May 16, 2026.